Question Bank › Ground-level proof points accumulating

Ground-level proof points accumulating

Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea

Calls Tested
322
Answered YES
8
Hit Rate
2.5%
rare by design

Akebia Therapeutics, Inc. (AKBA) — this company's answers

NO on the Q3 2021 call 2021-11-09 C+
The model's full reasoning — Q3 2021 call → NOWe need to answer based on the transcript. The question asks: On this call, does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside the business, each one identifiable on its own — AND does management explicitly treat these accumulating episodes as the LEADING EDGE of a broader improvement that is still early? We need to check both halves. The call is about Q3 2021 results. Management discusses vadadustat progress, Auryxia revenue, etc. Let's look for specific episodes. The call mentions: - FDA's completion of mid-cycle review and release of additional Phase 3 data at ASN Kidney Week. - Launch of vadadustat by partner MTPC in Japan over a year ago, and HIF-PHI share growing in Japan. - European marketing authorization submitted to EMA last month. - UT Health's investigator-sponsored study of vadadustat for ARDS, expanded beyond 400 patients. - Auryxia revenue growth, but that's aggregate. - Also mention of TDAPA, but that's future. Are these "small, concrete, ground-level wins"? The FDA mid-cycle review is a regulatory milestone, not a ground-level win like a customer signing. The ASN data presentation is a conference presentation. The EMA submission is a regulatory event. The UT Health study expansion is a clinical trial progress. These are not typical "wins" like specific customers or accounts. They are more like regulatory and clinical milestones. The question asks for "several small, concrete, ground-level wins" that are "individually identifiable" and "recent episodes from inside the business" like a particular customer, account, partner, site, product, etc. The examples given are operational-level facts. The call's positive story is mainly about vadadustat's regulatory progress and launch preparation. There is no mention of specific dialysis providers signing contracts, specific sales wins, etc. The Auryxia revenue growth is aggregate, not specific episodes. Also, management does not explicitly connect these episodes into a broader still-early pattern. They talk about preparing for launch, but they don't say "these wins are leading edge of a broader improvement." They mention that they are encouraged by developments, but they don't frame it as accumulating episodes leading to a larger trajectory. Thus, the answer is NO.

← Back to the full AKBA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside the business, each one identifiable on its own — AND does management explicitly treat these accumulating episodes as the LEADING EDGE of a broader improvement that is still early? Answer YES when BOTH halves come through in management's own words, in whatever form fits the business: (1) AT LEAST THREE DISTINCT, NAMED OR INDIVIDUALLY IDENTIFIABLE EPISODES FROM THE RECENT PERIOD. Management recounts multiple separate ground-level events that actually happened recently — each described specifically enough that a listener could tell the episodes apart and could later check them. The episodes may take whatever form fits the industry: a particular customer, account, or partner that signed, reordered, expanded, or went live; a particular site, store, plant, line, rig, clinic, or facility that opened, hit a milestone, or reached a new performance level; a particular product, program, or offering that shipped its first units, won its first placements, or crossed a threshold; a particular region, channel, or contract that turned on or stepped up. What matters is the GRANULARITY and RECENCY: these are individually small, freshly occurred, operator-level facts — the kind of detail only people close to the business would narrate — not aggregate results, percentages, themes, or claims like "demand was strong across the board." (2) MANAGEMENT ITSELF CONNECTS THE EPISODES INTO A BUILDING PATTERN THAT IS STILL EARLY. Management explicitly draws the line from these individual episodes to a larger developing trajectory — conveying, in its own voice, that these wins are instances of the same underlying thing, that more of the same kind are already forming or arriving, and that the pattern's contribution to reported results is only beginning, so most of it lies ahead. The generalization must be management's own act, grounded in the recounted episodes — not a hope, a market-size claim, or an analyst's summary. Answer NO if the call's positive story is carried mainly by aggregates — overall growth rates, segment percentages, or general demand commentary — without several individually identifiable recent episodes. NO if fewer than three distinct episodes are described, or the episodes are really one event told from different angles. NO if the episodes are plans, pipeline items, letters of intent, or hoped-for events rather than things that already happened. NO if the episodes are the routine cadence this company always reports (its usual pace of customer additions, standard seasonal openings) and management does not present their accumulation as new or building. NO if management recounts the episodes but never itself connects them into a broader, still-early pattern with more arriving. NO if the episodes chiefly explain problems, or the call is mainly defense of weak results. NO if the pattern-framing appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
TOST Toast, Inc. Q4 2022 2023-02-16 C+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...

More from the question bank

Conversion calendar in handFresh order-of-magnitude reference changeBetting on a customer they cannot yet nameOutside actors already movingWinning more per swing than they used to — aPriced for a smaller companyAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.